Back to resultsPiracetam for Treatment of Cocaine Addiction, Phase II - 4
Primary Purpose
Cocaine-Related Disorders
Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Piracetam
Sponsored by
About this trial
This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring cocaine
Eligibility Criteria
Please contact site for information.
Sites / Locations
- University of Pennsylvania
Outcomes
Primary Outcome Measures
Drug use
Adverse effects
Clinical status
Secondary Outcome Measures
Full Information
NCT ID
NCT00000199
First Posted
September 20, 1999
Last Updated
March 28, 2017
Sponsor
University of Pennsylvania
Collaborators
National Institute on Drug Abuse (NIDA)
1. Study Identification
Unique Protocol Identification Number
NCT00000199
Brief Title
Piracetam for Treatment of Cocaine Addiction, Phase II - 4
Official Title
Piracetam for Treatment of Cocaine Addiction, Phase II
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Withdrawn
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Pennsylvania
Collaborators
National Institute on Drug Abuse (NIDA)
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to follow patients in Phase I of an inpatient study in an eight week open label assessment of piracetam in an outpatient treatment program.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders
Keywords
cocaine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Piracetam
Primary Outcome Measure Information:
Title
Drug use
Title
Adverse effects
Title
Clinical status
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyle Kampman, M.D.
Organizational Affiliation
University of Pennsylvania
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104 6178
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Piracetam for Treatment of Cocaine Addiction, Phase II - 4
We'll reach out to this number within 24 hrs